Skip to main content
Jonathan Kaufman, MD, Oncology, Atlanta, GA, Emory University Hospital Midtown

JonathanLKaufmanMD

Oncology Atlanta, GA

Hematologic Oncology

Professor, Hematology and Medical Oncology, Winship Cancer Institute of Emory University

Dr. Kaufman is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Kaufman's full profile

Already have an account?

Summary

  • Dr. Jonathan Kaufman is a hematologist in Atlanta, GA and is affiliated with multiple hospitals in the area, including Emory University Hospital Midtown and Emory University Hospital. He received his medical degree from Medical College of Georgia School of Medicine and has been in practice 18 years. He is experienced in hematologic oncology, stem cell transplantation and cellular therapy.

Education & Training

  • Emory University School of Medicine
    Emory University School of MedicineFellowship, Hematology and Medical Oncology, 2001 - 2005
  • Emory University School of Medicine
    Emory University School of MedicineResidency, Internal Medicine, 1999 - 2001
  • Medical College of Georgia
    Medical College of GeorgiaClass of 1999

Certifications & Licensure

  • GA State Medical License
    GA State Medical License 2003 - 2023
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Abstracts/Posters

  • Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with ...
    Jonathan L. Kaufman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrang...
    Jonathan L. Kaufman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy
    Jonathan L. Kaufman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed ... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Challenges in Myeloma Therapy 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Efficacy and safety of daratumumab, lenalidomide, and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Updated subgroup analysis of POLLUX based... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Join now to see all

Press Mentions

  • Jonathan Kaufman, MD, Talks Targeting BCL-2 with Venetoclax and Dexamethasone in R/R MM
    Jonathan Kaufman, MD, Talks Targeting BCL-2 with Venetoclax and Dexamethasone in R/R MMMay 12th, 2021

Professional Memberships

Hospital Affiliations